Search | Clinical Trials Finder

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 8 more

Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions: Non-invasive hemodynamic measurements; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alcoholism
Interventions: Bronchoscopy, Zinc sulfate 220 mg once daily, S-adenosylmethionine 400 mg twice daily; Procedure · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Cancer
Interventions: Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine; Drug · Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non Small Cell Lung Cancer
Interventions: Pegilodecakin, Nivolumab; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Tempe, Arizona • Beverly Hills, California • Los Angeles, California + 30 more

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo, Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).; Dietary Supplement · Drug
Lead sponsor: Optimal Health Research; Other
Eligibility: 25 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: COVID-19
Interventions: Biological: COVID-19 convalescent plasma; Biological
Lead sponsor: Nakhle Saba, MD; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Small Cell Lung Cancer
Interventions: AMG 119; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV, Recurrent Lung Adenocarcinoma, Recurrent Lung Cancer
Interventions: Trametinib, Erlotinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Fibrosis Lung, Systemic Sclerosis
Interventions: Bronchoscopy with lavage; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer
Interventions: NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab; Drug
Lead sponsor: NeoTX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Daphne, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ranpirnase; Drug
Lead sponsor: Tamir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Beverly Hills, California • Grand Rapids, Michigan • Great Falls, Montana + 3 more

Conditions: Disorder Related to Lung Transplantation
Interventions: Alveoflex Confocal MiniprobeTM; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 22 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Embolism
Interventions: Denali inferior vena cava filter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more

Conditions: Pulmonary Hypertension
Interventions: Iloprost and nitric oxide administration; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Cancer, Oligometastatic Lung Tumor
Interventions: One fraction stereotactic body radiotherapy, HyperSight, Ethos; Radiation · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
Interventions: thalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: VIC-1911, sotorasib; Drug
Lead sponsor: Vitrac Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more

Conditions: Hypogammaglobulinemia, Lung Transplantation
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Heart Disease
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 8 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions: 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography, Echocardiography, Exercise Cardiac Stress Test, Questionnaire Administration, Single Photon Emission Computed Tomography; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH

Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics

Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma

Quality of Life in IPF - Patient and Physician Perceptions

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation